1. Scrip
  2. >>Focus On Asia
  3. >>Japan

First Asian launch for ulipristal, in South Korea

 
• By Ian Haydock

HRA Pharma has launched the emergency oral contraceptive ellaOne (ulipristal acetate) in South Korea through its licensee for this market, Hyundai Pharm.

HRA Pharma has launched the emergency oral contraceptive ellaOne (ulipristal acetate) in South Korea through its licensee for this market, Hyundai Pharm.

The prescription-only product is a successor to HRA's levonorgestrel-only emergency OC NorLevo, which has been available in South Korea for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.